A stronger financial position
Net profit margin was maintained at 11.1% and continuing rigorous financial management enabled the Company to generate largely positive free cash flow and reduce net financial debt by 14% to EUR 10.4 million.
ORALAIR(R) Grasses: impending registration of adult and paediatric indications.
The registration of ORALAIR(R) Grasses in Germany should be delivered shortly. The highly positive results of the VO52 paediatric study lead us to expect paediatric extension and a launch in both indications.
- Stallergenes expects further sales growth in 2008 (greater than or equal to 10%).
- The Group is actively preparing the commercial launch of ORALAIR(R) Grasses in Germany and now has an operational industrial platform.
- The laboratory plans to accelerate its R&D effort, which should account for 17% to 18% of sales in 2008, in order to support the current programme and the filing of an IND clinical study application in the US with a view to potential registration in this country.
- Lastly, the Company continues to study partnership proposals for the US.
The Board of Directors will propose to the General Meeting to be held on 30 May 2008, the distribution of a dividend of EUR 0.40 per share, reflecting a 14% increase over the previous year.
Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.
A pioneer and leader in sublingual desensitization treatments,
Stallergenes devotes 16% of its sales to Research and Development and is
today fully involved in the development of a
Copyright©2008 PR Newswire.
All rights reserved